Research Article

Genetic Variations in Nucleotide Excision Repair Pathway Genes and Risk of Allergic Rhinitis

Wenlong Liu, Qingxiang Zeng, Yinhui Zeng, Yiquan Tang, and Renzhong Luo

Department of Otolaryngology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China

Correspondence should be addressed to Wenlong Liu; lwl20103@163.com

Received 18 December 2021; Revised 14 May 2022; Accepted 26 May 2022; Published 3 June 2022

Academic Editor: Alex Kleinjan

Copyright © 2022 Wenlong Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Allergic rhinitis (AR) is the most frequent inflammatory disorder in the nasal mucosa that remains unclear etiology. Mounting studies suggested that genetic instability could trigger and worsen the inflammatory response. The nucleotide excision repair (NER) system is an important pathway in maintaining the stability of the genome. Therefore, the genetic variations in NER pathway genes may have potential effects on AR risk. Methods. We evaluated the correlation between 19 candidate single nucleotide polymorphisms (SNPs) in NER pathway genes and AR susceptibility by a case-control study in a Chinese population, which contains 508 AR cases and 526 controls. Results. Three independent SNPs were identified as significantly associated with AR susceptibility, including ERCC1 rs2298881 C > A (recessive model: adjusted odds ratios (OR) = 0.30, 95% confidence interval (CI) = 0.18 – 0.50, \( P < 0.0001 \)), ERCC1 rs11615 G > A (dominant model: adjusted OR = 1.44, 95% CI = 1.04 – 2.01, \( P = 0.03 \)), and XPC rs2228001 A > C (dominant model: adjusted OR = 0.68, 95% CI = 0.49 – 0.95, \( P = 0.024 \)). Stratified analysis showed that ERCC1 rs2298881 AA genotype was correlated with a lower risk of AR among all the subgroups compared with rs2298881 CC/CA genotype. XPC rs2228001 AC/CC genotype reduced AR risk among the following subgroups: age > 60 months, clinical stage I and III. Conclusion. Our finding showed that genetic variations in NER pathway genes: ERCC1 and XPC may affect the risk of AR, which will provide new insights into the genetics of AR from the perspective of DNA damage repair.

1. Introduction

Allergic rhinitis (AR) is defined as an immunoglobulin E-(IgE-) mediated nasal inflammatory disease and is characterized by allergic symptoms [1]. It affects more than 40% of children worldwide, and the incidence is still an increasing trend [2]. Currently, AR cannot be completely cured. AR has become a global health problem, which generates huge economic and social burdens [3, 4]. Therefore, it seems particularly important to identify the genetic risk factors and screen high-risk subjects, which could provide early intervention to prevent the occurrence of AR.

The occurrence and development of AR were attributed to the aberration of regulatory T (Treg) cells, the imbalance between Th1 and Th2 immune response, the excessive secretion of proinflammatory cytokines, and the selective accumulation in the nasal mucosa of various immune cells [5, 6]. Current studies generally believe that the interaction of environmental and genetic factors jointly determines the genesis and progression of AR [7–9]. Environmental exposure to mold stains, fungal allergens, pollens, and dust mites could initiate and exacerbate the AR [10, 11], while genetic factors may exert more significant effects on the development, severity, and treatment of AR [12, 13]. The twins’ studies revealed that the inheritability of AR reaches 0.33–0.75 [14, 15].

Numerous genetic studies suggested that single nucleotide polymorphisms (SNPs) in the key genes involved in the pathogenesis of AR contribute greatly to AR susceptibility, which can be classified as interleukin, chemokines, and their corresponding receptors [16, 17]. The SNPs in the interleukin such as IL4 [18], IL6 [8], IL13 [19], IL18 [20], and IL33 [9] have been reported associated with the risk of AR, which are the key regulators in the progression of AR.
Numerous studies suggested that there is a complex relationship between genomic instability and inflammation. The DNA damage events can activate the proinflammatory signals and then exacerbate the inflammatory response. The inflammation also contributes to DNA damage by producing nitrogen species (RNS) and reactive oxygen species (ROS). This positive feedback loop was finely regulated through a complex network of transcription factors, cellular signals, and DNA damage repair pathways [21]. DNA damage also can activate certain inflammation regulators, such as NfκB, a crucial transcription factor that contributes to inflammatory response greatly through facilitating transcription of proinflammatory genes [22]. Additionally, DNA damage can trigger necrosis and senescence, which also enhance the inflammatory signals by releasing many inflammatory cytokines [23, 24]. The nucleotide excision repair (NER) system is a crucial DNA repair pathway that is responsible for maintaining the integrity of the genome, and it primarily repairs bulky DNA lesions. Several core genes accomplish the repair process coordinately, including ERCC1, XPA, XPC, XPD, XPF, and XPG. Mutations and abnormal expression of these core genes may affect the NER activity and the DNA repair efficiency thus increasing genetic instability and eventually leading to cancers or inflammatory disorders. Previous studies have shown that SNPs in NER pathway genes are significantly associated with the risks of various cancers [25]. For instance, Zhuo et al. have found XPC genetic variant was susceptible to hepatoblastoma risk [26]. The association between ERCC1 SNPs and altered gastric cancer risk has been demonstrated by He et al. [27].

However, no study reports the associations between genetic variations in NER pathway genes and AR risk. Hence, we performed this current case-control study to assess this association and identified AR risk-associated genetic markers from the NER pathway, which may help to screen the individuals with a high risk of AR and make early interventions to prevent the occurrence and development of AR.

2. Methods

2.1. Study Population. In this present case-control study, 508 AR cases and 526 healthy controls were included. All the subjects are of Chinese origin and recruited from Guangzhou Women and Children’s Medical Center (Guangzhou, Guangdong province, China). The diagnostic criteria were followed the Allergic Rhinitis and Impact on Asthma (ARIA) guideline criteria [28].

In brief, AR cases were recruited and diagnosed by ENT doctors according to classic nasal symptoms and positive allergens test confirmed by skin prick test or specific IgE measurement. Patients with other comorbid diseases (such as asthma and allergic dermatitis) and other systematic diseases were excluded. The severity of AR was classified according to the degree of influence level of sleep, daily activities, and work and/or school performance (mild, no influence; moderate, impair above activities; severe, severely impair above activities). The informed consent forms were signed by the guardian of all participants before the research. The study protocol was authorized by the hospital institutional review board.

2.2. SNP Selection and Genotyping. Potential functional SNPs among the NER core genes were selected via the dbSNP database and SNP info as described by previous research [29]. A total of 19 candidate functional SNPs in six genes of the NER pathway were identified eventually for analysis. For genotyping, the genomic DNA from the peripheral blood of all subjects was extracted and purified by applying the TIANamp Blood DNA Kit (TianGen Bio-tech, Beijing, China). The TaqMan real-time PCR was performed in the 384-well format for genotyping of 19 candidate SNPs among all DNA samples. The conditions of reactions were set as follow: preread stage at 60°C for 30 seconds, holding stage at 95°C 10 minutes, repeated 45 cycles each of denaturation at 95°C for 15 seconds, and annealing and extension at 60°C for 1 minute. Then, we selected standard run mode and added the reaction volume (5 μL for each well in 384-well reaction plate) into the instrument. Finally, we loaded the reaction plate, then start the run. To ensure the reliability and authenticity of the results, a second-time genotyping was conducted in randomly selected 10% DNA samples. Two sets of results were 100% consistent.

2.3. Expression Quantitative Trait Loci (eQTL) Analysis. The eQTL is a kind of specific genetic maker that spread over genomes, which may affect gene expressions. The public databases from GTEx (Genotype-Tissue Expression) platform are usually used to analyze the correlation between genetic variants and gene expressions. Here, we performed the eQTL analysis to evaluate the bioeffect of associated SNPs on gene expression by applying the released data from GTEx Portal. The details of GTEx and analysis were reported in the previous publications [30].

2.4. Statistical Analysis. The goodness-of-fit χ² test was used to evaluate whether the 19 candidate SNPs were in Hardy-Weinberg equilibrium (HWE) among control subjects. Differences in allele frequencies of selected SNPs between cases and controls were assessed using Pearson’s chi-square test. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the association between 19 candidate SNPs and AR susceptibility. And the unconditional multivariate logistic regression analysis that adjusted for age and sex was conducted to calculate adjusted ORs and corresponding 95% CIs. Additionally, stratification analysis was performed in terms of age, gender, and clinical stage of subjects. The statistical analyses were performed in the SAS statistical software (version 9.4, SAS Institute, NC, USA). The result would be regarded as statistically significant when P value < 0.05.

3. Results

3.1. Correlations between SNPs of NER Pathway Genes and AR Susceptibility. In this present case-control study, 508 AR cases and 526 healthy controls were included for
analyzing the correlations between 19 candidate SNPs and AR susceptibility. As displayed in Table 1, the observed genotype frequencies of all selected SNPs are consistent with Hardy-Weinberg equilibrium (HWE) among the controls \((P > 0.05)\). We discovered that ERCC1 rs2298881 C > A was associated with decreased AR susceptibility, and carriers with rs2298881 AA genotype had significantly reduced AR risk when compared to subjects with CC/CA genotype \((AOR = 0.30, 95\% CI = 0.18 – 0.50, P < 0.0001, \text{ recessive model})\). However, another SNP in ERCC1: rs11615 G > A was found to be related to increased risk of AR, and subjects with GA/AA genotype have higher AR risk compared to those with GG genotype \((AOR = 1.44, 95\% CI = 1.04 – 2.01, P = 0.030, \text{ dominant model})\). In addition, we also identified XPC rs2228001 A > C was correlated with reduced AR susceptibility, and individuals with AC/CC genotype have a lower risk of AR compared to those with AA genotype \((AOR = 0.68, 95\% CI = 0.49 – 0.95, P = 0.024, \text{ dominant model})\). For the rest of the SNPs, no significant effect was found in AR risk \((P > 0.05)\).

### 3.2. Stratified Analysis

To eliminate potential effect of age, gender, and clinical stages on AR risk, we further performed the stratified analysis through adjusting these confounding factors. As displayed in Table 2, the protective effect of rs2298881 AA genotype in reducing AR risk was observed among all subgroup: age ≤ 60 months \((AOR = 0.40, 95\% CI = 0.20 – 0.77, P = 0.007)\), age > 60 \((AOR = 0.46, 95\% CI = 0.26 – 0.80, P = 0.007)\), females \((AOR = 0.25, 95\% CI = 0.12 – 0.55, P = 0.0004)\), males \((AOR = 0.35, 95\% CI = 0.18 – 0.68, P = 0.002)\), clinical I \((AOR = 0.44, 95\% CI = 0.23 – 0.85, P = 0.015)\), clinical II \((AOR = 0.24, 95\% CI = 0.12 – 0.46, P < 0.0001)\), and clinical III \((AOR = 0.39, 95\% CI = 0.20 – 0.79, P = 0.009)\). However, the significant risk effect of rs11615 G > A in AR was not found among all subgroups \((P > 0.05)\). And XPC rs2228001 AC/CC genotype decreased the AR risk among following subgroups: age > 60 \((AOR = 0.58, 95\% CI = 0.37 – 0.93, P = 0.022)\), clinical I \((AOR = 0.44, 95\% CI = 0.28 – 0.69, P = 0.0004)\), and clinical III \((AOR = 0.51, 95\% CI = 0.31 – 0.82, P = 0.006)\).

### 3.3. eQTL Analysis

To further explore the potential biologic effects of the significant SNPs on the adjacent gene expressions and the possible mechanism by which these significant SNPs modify AR susceptibility, we performed the eQTL analysis from the GTEx platform. We discovered that the rs2298881 A allele was significantly related to decreased mRNA expression of ERCC1 in the cell-cultured fibroblasts and whole blood (Figure 1(a)). However, another significant SNP in ERCC1: rs11615 G > A was not associated with the mRNA level of ERCC1 but affected the gene expression of CD3EAP. The CD3EAP mRNA with ERCC1 rs11615 G allele was significantly lower than those with ERCC1 rs11615 A allele in the cell-cultured fibroblasts (Figure 1(b)). For the SNP rs2228001, the T allele was found to be significantly associated with lower mRNA levels of CHCHD4 and XPC compared to those with the G allele in the cell-cultured fibroblasts (Figure 1(c)).

### 4. Discussion

To explore the effects of SNP in NER pathway genes on AR susceptibility, we performed this current case-control research in the Chinese population which comprehensively assessed the association between 19 functional SNPs in 6 NER core genes and AR risk. Our results showed that two SNPs (rs2298881 C > A and rs11615 G > A) in the ERCC1 gene and one SNP (rs2228001 A > C) in the XPC gene were significantly associated with AR risk. To the best of our knowledge, this research is the first study that systematically evaluated the relationship between multiple functional SNPs in NER pathway genes and AR susceptibility. Our findings may help screen the high-risk groups and make early interventions of AR, which will greatly reduce its morbidity.

Although being subject of extensive study, the pathogenesis of AR is still poorly understood, which might attribute to its intricate etiology that involves the complex interactions of genetic and environmental factors [31, 32]. However, mounting studies have shown that genetic factors exert significant effects on the genesits, severity, and response to treatment of AR [33]. Numerous studies revealed that SNP in certain pivotal genes involved in the pathology of AR, such as interleukin, chemokine, and their receptor coding genes, will modify the susceptibility of AR. For example, IL4 and IL13 are known for their key role in the pathogenesis of AR. One SNP rs2243250 C > T located in the promoter region of IL4 was shown associated with an increased risk of AR. The further study uncovered that this SNP can upregulate the expression of IL4 and increase the plasma IgE subsequently, which will exacerbate the symptoms of AR eventually [33]. Furthermore, another SNP rs20541 A > C located in exon 4 of IL13 was demonstrated increasing the risk of AR in Asian populations significantly [19]. Functional studies discovered that SNP rs20541 A > C results in an amino acid change from glutamine to arginine, which is involved in the transcriptional activity and increases the activity or signaling of IL13. It was reported that rs20541 A allele was related to higher serum IL13 and IgE levels, which contributed to an increase of eosinophil counts and increased risk of AR [34, 35].

Despite it being widely believed that DNA damage was one of the most common events in cancer, however, growing studies showed that genomic instability also triggers inflammatory responses. Previous researches have shown that some crucial transcription factors were activated during inflammation, such as HMGB1 and NFKB, which caused and aggravate inflammatory responses by augmenting the expression of downstream proinflammatory cytokines [36, 37]. In addition, DNA damage-driven senescence or apoptosis also exacerbates the inflammatory response by releasing various inflammatory factors or other ways [38, 39]. Therefore, genetic instability may be an important source of proinflammatory signals and promote the development of inflammation.

The NER pathway is the primary repair mechanism for DNA damage, which plays an important role in maintaining genomic stability and preventing the occurrence of diseases, such as various cancers and inflammations. The NER
process is completed collaboratively by the NER machinery that is composed of several crucial enzymes: ERCC-1 and XPF encode 5′ endonucleases, XPA, and XPC function as damage recognition, XPD gene encodes the helicase and DNA repair efficiency, which may modify the susceptibility of various disorders. Numerous studies have shown significant associations between SNP of NER core genes and DNA repair efficiency, which may modify the susceptibility of various disorders. Various studies have shown significant associations between SNP of NER core genes and multiple cancers susceptibilities [25, 43, 44]. Whereas, scarcely any study reported this association in inflammatory disease, including AR.

In this current study, we as a vanguard to first comprehensively assessed the association between 19 SNPs in 6 NER core genes and AR susceptibility. Here, we identified three SNPs: ERCC1 rs2298881 C > A, ERCC1 rs11615 G > A, and XPC rs2228001 A > C were significantly associated with AR susceptibility. Detailed ERCC1 rs2298881 AA genotype decreased AR risk significantly when compared with CC/CA genotype. However, ERCC1 rs11615 GA/AA genotype was found to increase AR risk compared with the GG genotype. And XPC rs2228001 AC/CC genotype also reduced the risk of AR compared with those with AA genotype. The stratification analysis further showed that the protective effect of ERCC1 rs2298881 AA genotype was observed among all subgroups: age ≤ 60 months, age > 60 months, females, males, clinical I, clinical II, and clinical III. But the risk effect of ERCC1 rs11615 GA/AA genotype was disappeared among all subgroups. Maybe these confounding factors (age, gender, and clinical stages) have certain potential effects on AR risk, or it is just a chance finding attributed to the relatively small sample size in the stratified analysis. And carriers with XPC rs2228001 AC/CC genotype had a lower risk of AR compared with those with AA genotype in the following subgroups: age > 60 months, clinical I, and clinical III. The proteins of ERCC1 and XPC play an essential role during the NER process because of their excision and damage recognition ability. The ERCC1 protein can form a heterodimer with the XPF, and the complex that catalyzes the incision of 5′ phosphodiester backbone around the DNA damage sites was an indispensable component in the NER. And the protein of XPC can also form the heterodimer with the HR23B, and the complex that catalyzes the incision of 5′ phosphodiester backbone around the DNA damage sites was an indispensable component in the NER.

### Table 1: Association between polymorphisms in nucleotide excision repair pathway genes and allergic rhinitis susceptibility.

| Gene | SNP | Allele     | Case (N = 508) | Control (N = 526) | Adjusted OR | P | Adjusted OR | P | HWE |
|------|-----|-----------|---------------|------------------|-------------|---|--------------|---|------|
|      |     | A | B | AA | AB | BB | AA | AB | BB | (95% CI) | (95% CI) |     |
| ERCC1 | rs2298881 | C | A | 225 | 231 | 52 | 205 | 231 | 90 | 0.89 (0.64-1.24) | 0.493 | **0.30 (0.18-0.50)** | <0.0001 | 0.075 |
| ERCC1 | rs3212986 | C | A | 199 | 242 | 67 | 243 | 222 | 61 | 1.38 (0.99-1.92) | 0.060 | 1.14 (0.69-1.87) | 0.617 | 0.346 |
| ERCC1 | rs11615 | G | A | 261 | 204 | 43 | 297 | 185 | 44 | **1.44 (1.04-2.01)** | **0.030** | 0.99 (0.54-1.81) | 0.975 | 0.052 |
| XPA  | rs1800975 | T | C | 142 | 277 | 89 | 126 | 276 | 124 | 0.74 (0.51-1.07) | 0.106 | 0.78 (0.52-1.17) | 0.277 | 0.257 |
| XPA  | rs3176752 | G | T | 357 | 138 | 13 | 395 | 123 | 8 | 1.01 (0.70-1.46) | 0.942 | 1.48 (0.49-4.53) | 0.489 | 0.653 |
| XPC  | rs2282001 | A | C | 227 | 220 | 61 | 208 | 251 | 67 | **0.68 (0.49-0.95)** | **0.024** | 0.88 (0.53-1.47) | 0.632 | 0.517 |
| XPC  | rs2228000 | C | T | 184 | 247 | 77 | 206 | 249 | 71 | 1.12 (0.80-1.56) | 0.527 | 1.44 (0.90-2.31) | 0.131 | 0.756 |
| XPC  | rs2607775 | C | G | 463 | 45 | 0 | 473 | 53 | 0 | 0.90 (0.50-1.60) | 0.718 | / | / | 0.224 |
| XPC  | rs1870134 | G | C | 317 | 161 | 30 | 335 | 165 | 26 | 1.18 (0.84-1.65) | 0.338 | 1.27 (0.62-2.59) | 0.514 | 0.335 |
| XPC  | rs2229090 | G | C | 168 | 249 | 91 | 196 | 252 | 78 | 1.21 (0.86-1.70) | 0.276 | 1.28 (0.82-1.98) | 0.274 | 0.837 |
| XPD  | rs3810366 | G | C | 148 | 265 | 95 | 146 | 251 | 129 | 1.05 (0.73-1.51) | 0.782 | 0.87 (0.58-1.30) | 0.494 | 0.306 |
| XPD  | rs238406 | G | T | 114 | 266 | 128 | 152 | 248 | 126 | 1.22 (0.84-1.79) | 0.294 | 0.94 (0.64-1.38) | 0.753 | 0.209 |
| XPD  | rs131811 | C | T | 436 | 69 | 3 | 456 | 66 | 4 | 1.21 (0.75-1.95) | 0.447 | 2.90 (0.51-16.32) | 0.228 | 0.351 |
| XPG  | rs2276466 | C | G | 289 | 195 | 24 | 299 | 195 | 32 | 0.94 (0.67-1.31) | 0.709 | 0.74 (0.35-1.58) | 0.441 | 0.978 |
| XPG  | rs2094258 | C | T | 214 | 231 | 63 | 201 | 249 | 76 | 0.78 (0.56-1.08) | 0.132 | 0.89 (0.55-1.44) | 0.640 | 0.937 |
| XPG  | rs751402 | C | T | 205 | 235 | 68 | 209 | 235 | 82 | 0.85 (0.61-1.19) | 0.347 | 1.04 (0.66-1.64) | 0.851 | 0.241 |
| XPG  | rs2296147 | T | C | 321 | 165 | 22 | 341 | 166 | 19 | 1.27 (0.90-1.79) | 0.172 | 0.79 (0.34-1.86) | 0.589 | 0.828 |
| XPG  | rs1047768 | T | C | 270 | 200 | 38 | 309 | 189 | 28 | 1.33 (0.96-1.85) | 0.092 | 1.29 (0.68-2.48) | 0.438 | 0.897 |
| XPG  | rs873601 | A | G | 124 | 244 | 140 | 132 | 269 | 125 | 0.97 (0.66-1.42) | 0.865 | 1.45 (1.00-2.12) | 0.053 | 0.598 |

OR: odds ratio; CI: confidence interval; HWE: Hardy–Weinberg equilibrium. The results were in bold if the 95% CI excluded 1 or P < 0.05. *Adjusted for age and sex for dominant model. **Adjusted for age and sex for recessive model.
Table 2: Stratification analysis of ERCC1 and XPC genotypes with allergic rhinitis risk.

| Variables                  | ERCC1 rs2298881 (case/control) | ERCC1 rs11615 (case/control) | XPC rs2228001 (case/control) |
|----------------------------|---------------------------------|------------------------------|-------------------------------|
|                            | CC/CA                           | AA                           | AOR (95% CI)                  | P<0.05                        | AOR (95% CI)                  | P<0.05                        |
| Age, month                 |                                 |                              |                               |                               |                               |                               |
| ≤60                        | 153/356                         | 11/66                        | 0.40 (0.20-0.77)              | 0.007                         | 78/237                        | 86/185                        | 1.40 (0.97-2.01)              | 0.072                         | 73/175                        | 91/247                        | 0.89 (0.62-1.28)              | 0.522                         |
| >60                        | 303/80                          | 41/24                        | 0.46 (0.26-0.80)              | 0.007                         | 183/60                        | 161/44                        | 1.20 (0.77-1.87)              | 0.419                         | 154/33                        | 190/71                        | 0.58 (0.37-0.93)              | 0.022                         |
| Sex                        |                                 |                              |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |
| Females                    | 235/205                         | 22/36                        | 0.25 (0.12-0.55)              | 0.004                         | 132/129                       | 125/112                       | 1.37 (0.84-2.22)              | 0.209                         | 120/98                        | 137/143                       | 0.66 (0.40-1.08)              | 0.094                         |
| Males                      | 221/231                         | 30/54                        | 0.35 (0.18-0.68)              | 0.002                         | 129/168                       | 122/117                       | 1.52 (0.97-2.39)              | 0.068                         | 107/110                       | 144/175                       | 0.70 (0.44-1.10)              | 0.120                         |
| Clinical stages            |                                 |                              |                               |                               |                               |                               |                               |                               |                               |                               |                               |                               |
| I                          | 130/436                         | 17/90                        | 0.44 (0.23-0.85)              | 0.015                         | 80/297                        | 67/229                        | 1.24 (0.79-1.95)              | 0.341                         | 79/208                        | 68/318                        | 0.44 (0.28-0.69)              | 0.0004                        |
| II                         | 208/436                         | 19/90                        | 0.24 (0.12-0.46)              | <0.0001                       | 108/297                       | 119/229                       | 1.47 (0.99-2.18)              | 0.058                         | 84/208                        | 143/318                       | 0.89 (0.59-1.34)              | 0.587                         |
| III                        | 118/436                         | 16/90                        | 0.39 (0.20-0.79)              | 0.009                         | 73/297                        | 61/229                        | 1.24 (0.77-2.00)              | 0.369                         | 64/208                        | 70/318                        | 0.51 (0.31-0.82)              | 0.006                         |

CI: confidence interval; AOR: adjusted odds ratio. The results were in bold if the 95% CI excluded 1 or P<0.05. * Obtained in logistic regression models with adjustment for age and sex omitting the corresponding stratification factor.
modify the disease risk, especially cancers. For example, He et al. showed that the rs2298881 C allele and rs11615 A allele increased the susceptibility of gastric cancer [45]. And Malik et al. suggested that rs2228001 A>C may change the C-terminus functional preferences and structure of XPC, then contribute to the breast cancer risk [46]. However, no study reports the association between the SNP in NER pathway genes and AR susceptibility. Here, we first reported that SNP in ERCC1 (rs2298881 C>A and rs11615 G>A) and XPC (rs2228001 A>C) genes modify the risk of AR.

How these associated SNP modify the AR susceptibility? Interestingly, a recent study has introduced compelling evidence about shorter telomere lengths (TLs) among patients with AR. TLs as biomarkers of aging are prompted shortening by raised inflammation [47]. As a DNA repair protein, the ERCC1 may have influenced TLs wane procedure, such as sheltering them from homologous recombination [48], mediating a suppressive role in TLs maintenance by controlling the critical factor, TRF2 [49]. Because of the significant difference of ERCC1 genetic variation between AR and controls in our finding, which, therefore denotes the difference in TLs between them.

To further explore the functional effects of these significant SNPs on the expression of adjacent genes, then dope out the possible mechanisms by which the associated SNPs affect the AR risk, the eQTL analysis was carried out. Our results showed that rs2298881 A allele was significantly associated with lower mRNA expression of ERCC1 in the cell-

---

**Figure 1**: Expression quantitative trait loci (eQTL) analysis of the allergic rhinitis risk factors ERCC1 rs2298881 C > A, ERCC1 rs11615 G > A, and XPC rs2228001 A > C. (A) ERCC1 rs2298881 C > A genotype-based mRNA expression alteration of ERCC1 gene in the cells-cultured fibroblasts (a) and whole blood (b); (B) ERCC1 rs11615 G > A genotype-based mRNA expression change of CD3EAP gene in the cell-cultured fibroblasts; (C) XPC rs2228001 A > C genotype-based mRNA expression change of CHCHD4 (a) and XPC (b) genes in the cells-cultured fibroblasts.
cultured fibroblasts and whole blood, and rs11615 G allele was found to reduce the mRNA level of CD3EAP. Regarding rs2228001, the T allele was related to decreased expression of CHCHD4 and XPC. Maybe these SNP-base expression changes of neighboring genes contribute to the modification of genotype-base AR risk. However, further study is still needed to illuminate the exact underlining mechanisms. Although in the initial stage, our study provides new insights into the modification of AR risk by the NER pathway gene variants.

There are several concomitant limitations in this study. First, the present case-control study is hospital-based, so the selection bias is ineluctable. Second, the sample size enrolled in this study remained moderate, however, it was relatively small for stratified analysis, which may whittle the statistical power and reduce the reliability of the conclusions. Third, although we have made a comprehensive assessment on 19 SNP of NER pathway genes, other potentially functional SNP should be assessed. Fourth, environmental factors should be considered, as the etiology of AR involves complex interactions between multiple genetic and environmental factors. Fifth, the conclusions from this research may not apply to any ethnic group other than the Chinese, because of the Chinese origin of all participants. Sixth, mechanism studies should be included, which will further elucidate the underlying mechanism by which genetic variations in NER pathway genes modify AR risk. Seventh, most of AR cases in this study were perennial and caused by indoor allergen, especially house dust mite (>90%). Therefore, despite that there may be significant differences in pathogenesis between perennial and seasonal rhinitis, we believe that there may be less effect on our study. However, further study on seasonal rhinitis was also needed.

5. Conclusions

In summary, this current research was the first case-control study to systematically evaluate the effects of SNPs in NER-associated genes on AR risk. Our findings showed that in Chinese children, genetic variations in ERCCI and XPC genes influence AR susceptibility significantly. Well-designed studies with a large sample size involving different ethnicities should be performed to verify our conclusions in the future. Further, the potentially exact mechanisms that ERCCI and XPC genetic variants modify AR susceptibility should be revealed by further functional studies.

Data Availability

The datasets used and analyzed during the current study are all available from the corresponding author.

Conflicts of Interest

The authors declare that they have no relevant conflicts of interest.

Authors’ Contributions

Wenlong Liu, Qingxiang Zeng, and Yinhui Zeng contribute equally to this study.

Acknowledgments

This study was funded by grants from the National Natural Science Grant of China (no. 81970861), the Guangdong Province Natural Science Grant (no. 2021A1515010940), and the Science and Technology Program of Guangzhou (no. 202102020079).

References

[1] D. V. Wallace, M. S. Dykewicz, D. I. Bernstein et al., “The diagnosis and management of rhinitis: an updated practice parameter,” The Journal of Allergy and Clinical Immunology, vol. 122, no. 2, pp. S1–84, 2008.
[2] T. Lancet, “Allergic rhinitis: common, costly, and neglected,” Lancet, vol. 371, no. 9630, article 2057, 2008.
[3] R. A. Settipane and D. R. Charnock, “Epidemiology of rhinitis: allergic and nonallergic,” Clinical Allergy and Immunology, vol. 19, pp. 23–34, 2007.
[4] D. Price, P. Smith, P. Hellings et al., “Current controversies and challenges in allergic rhinitis management,” Expert Review of Clinical Immunology, vol. 11, no. 11, pp. 1205–1217, 2015.
[5] R. Pawankar, S. Mori, C. Ozu, and S. Kimura, “Overview on the pathomechanisms of allergic rhinitis,” Asia Pacific Allergy, vol. 1, no. 3, pp. 157–167, 2011.
[6] K. Botturi, Y. Lacoeuilhe, A. Cavaillès, D. Vervloet, and A. Magnan, “Differences in allergen-induced T cell activation between allergic asthma and rhinitis: role of CD28, ICOS and CTLA-4,” Respiratory Research, vol. 12, no. 1, pp. 1–10, 2011.
[7] Y. Meng, C. Wang, and L. Zhang, “Recent developments and highlights in allergic rhinitis,” Allergy, vol. 74, no. 12, pp. 2320–2328, 2019.
[8] N. Zhao, H. J. Liu, Y. Y. Sun, and Y. Z. Li, “Role of interleukin-6 polymorphisms in the development of allergic rhinitis,” Genet Mol Res, vol. 15, no. 1, 2016.
[9] H. Ran, H. Xiao, X. Zhou, L. Guo, and S. Lu, “Single-nucleotide polymorphisms and haplotypes in the interleukin-33 gene are associated with a risk of allergic rhinitis in the Chinese population,” Experimental and Therapeutic Medicine, vol. 20, no. 5, p. 102, 2020.
[10] D. P. Skoner, “Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis,” The Journal of Allergy and Clinical Immunology, vol. 108, no. 1, pp. S2–S8, 2001.
[11] J. Dunlop, E. Matsui, and H. P. Sharma, “Allergic rhinitis: environmental determinants,” Immunology and Allergy Clinics of North America, vol. 36, no. 2, pp. 367–377, 2016.
[12] D. Vercelli, “Genetic polymorphism in allergy and asthma,” Current Opinion in Immunology, vol. 15, no. 6, pp. 609–613, 2003.
[13] A. K. Andiappan, D. Nilsson, C. Hallén et al., “Investigating highly replicated asthma genes as candidate genes for allergic rhinitis,” BMC Medical Genetics, vol. 14, no. 1, article 51, 2013.
[14] M. Feijen, J. Gerritsen, and D. S. Postma, “Genetics of allergic disease,” British Medical Bulletin, vol. 56, no. 4, pp. 894–907, 2000.
Mediators of Inflammation

[15] C. Fagnani, I. Annesi-Maesano, S. Bresciaianini et al., “Heritability and shared genetic effects of asthma and hay fever: an Italian study of young twins,” Twin Research and Human Genetics, vol. 11, no. 2, pp. 121–131, 2008.

[16] I. Davila, J. Mullol, M. Ferrer et al., “Genetic aspects of allergic rhinitis,” Journal of Investigational Allergology & Clinical Immunology, vol. 19, Suppl 1, pp. 25–31, 2009.

[17] E. Guertes, M. Brauer, E. MacIntyre et al., “Childhood allergic rhinitis, traffic-related air pollution, and variability in the GSTP1, TNF, TLR2, and TLR4 genes: results from the TAG Study,” The Journal of Allergy and Clinical Immunology, vol. 132, no. 2, pp. 342–352.e2, 2013, e342.

[18] S. Micheal, K. Minhas, M. Ishaque, F. Ahmed, and A. Ahmed, “IL-4 gene polymorphisms and their association with atopic asthma and allergic rhinitis in Pakistani patients,” Journal of Investigational Allergology & Clinical Immunology, vol. 23, no. 2, pp. 107–111, 2013.

[19] M. L. Chen, H. Zhao, Q. P. Huang, and Z. F. Xie, “Toll-like receptor 4 engagement inhibits adenosine 5’-monophosphate-activated protein kinase activation through a high mobility group box engagement inhibits adenosine 5’-monophosphate-activated protein kinase activation through a high mobility group box,” Journal of Cell Science, vol. 124, no. 1, pp. 68–75, 2011.

[20] S. Xu, J. X. Zhang, “ADAM33 polymorphisms and susceptibility to allergic rhinitis: a meta-analysis,” European Archives of Oto-Rhino-Laryngology, vol. 275, no. 6, pp. 1491–1500, 2018.

[21] P. Tharabenjasin, N. Pabalan, H. Jarjanazi, and S. J. Martin, “Toll-like receptor 4 engagement inhibits adenosine 5’-monophosphate-activated protein kinase activation through a high mobility group box 1 protein-dependent mechanism,” Molecular Medicine, vol. 18, no. 4, pp. 659–668, 2012.

[22] P. Davidovich, C. J. Kearney, and S. J. Martin, “Inflammatory outcomes of apoptosis, necrosis and necroptosis,” Biological Chemistry, vol. 395, no. 10, pp. 1163–1171, 2014.

[23] F. Rodier, J. P. Coppé, C. K. Patil et al., “Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion,” Nature Cell Biology, vol. 11, no. 8, pp. 973–979, 2009.

[24] Z. Zhuo, L. Miao, W. Hua et al., “Genetic variations in nucleotide excision repair pathway genes and hepatoblastoma susceptibility,” International Journal of Cancer, vol. 149, no. 9, pp. 1649–1658, 2021.

[25] J. He, Z. J. Zhuo, A. Zhang et al., “Genetic variants in the nucleotide excision repair pathway genes and gastric cancer susceptibility in a southern Chinese population,” Cancer Management and Research, vol. Volume 10, pp. 765–774, 2018.

[26] A. Shirkani, A. Mansouri, M. R. Abbassadeghan, R. Faridhosseini, F. Jabbari Azad, and M. Gholamin, “<c>1>GATA3</c> gene polymorphisms associated with allergic rhinitis in an Iranian population,” Reports of Biochemistry & Molecular Biology, vol. 5, no. 2, pp. 97–102, 2017.

[27] J. He, L. X. Qiu, M. Y. Wang et al., “Polymerorphisms in the XPG gene and risk of gastric cancer in Chinese populations,” Human Genetics, vol. 131, no. 7, pp. 1235–1244, 2012.

[28] L. J. Carithers and H. M. Moore, “The genotype-tissue expression (GTEx) project,” Biopreservation and Biobanking, vol. 13, no. 5, pp. 307–308, 2015.

[29] J. Liu, C. He, C. Xing, and Y. Yuan, “Nucleotide excision repair related gene polymorphisms and genetic susceptibility, chemotherapeutic sensitivity and prognosis of gastric cancer,” Mutation Research, vol. 765, pp. 11–21, 2014.

[30] J. Liu, C. He, C. Xing, and Y. Yuan, “Nucleotide excision repair related gene polymorphisms and genetic susceptibility, chemotherapeutic sensitivity and prognosis of colorectal cancer,” World Journal of Gastroenterology, vol. 26, no. 3, pp. 307–323, 2020.
[45] J. He, Y. Xu, L. X. Qiu et al., "Polymorphisms in ERCC1 and XPF genes and risk of gastric cancer in an eastern Chinese population," *PloS One*, vol. 7, no. 11, article e49308, 2012.

[46] S. S. Malik, A. Zia, S. Rashid et al., "XPC as breast cancer susceptibility gene: evidence from genetic profiling, statistical inferences and protein structural analysis," *Breast Cancer*, vol. 27, no. 6, pp. 1168–1176, 2020.

[47] K. T. Tung, R. S. Wong, H. W. Tsang et al., "Impact of snoring on telomere shortening in adolescents with atopic diseases," *Genes*, vol. 12, no. 5, article 766, 2021.

[48] J. B. Vannier, A. Depeiges, C. White, and M. E. Gallego, "ERCC1/XPF protects short telomeres from homologous recombination in Arabidopsis thaliana," *PLoS Genetics*, vol. 5, no. 2, article e1000380, 2009.

[49] Y. Wu, T. R. Mitchell, and X. D. Zhu, "Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms," *Mechanisms of Ageing and Development*, vol. 129, no. 10, pp. 602–610, 2008.